What the BPC-157 literature actually shows: the proposed mechanisms (VEGFR2, FAK-paxillin, growth hormone receptor, nitric oxide), the rodent and cell models behind them, what is known about its pharmacokinetics, and where the evidence is still thin.
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide whose sequence is a partial fragment of a protein described in human gastric juice. Over three decades it has been studied in a wide range of injury models, from gastric lesions to transected tendons, and it is one of the most frequently discussed research peptides. This overview is written for researchers who want to know what that literature consists of: which mechanisms have been proposed and in what systems, what the key experiments measured, and which questions remain open.
BPC-157 has the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV) and a molecular weight of about 1,419 Da. It is not the full native protein but a stable fragment of it, and the group that first characterized it describes the peptide as stable in human gastric juice [1]. That stability is why the literature often calls it the 'stable gastric pentadecapeptide.'
Chemically the sequence is simple to work with. It carries three acidic residues (one glutamate, two aspartates) and one lysine, so it is net negative at neutral pH, and it contains none of the residues most prone to oxidation (methionine, cysteine, tryptophan).
Before looking at individual findings, it helps to know the shape of the literature. A 2019 critical review found that nearly all BPC-157 studies had been performed in small rodent models, that efficacy had not been confirmed in humans, and that only a handful of research groups had studied the peptide in depth over two decades [3]. A 2025 systematic review focused on musculoskeletal research screened 544 records and included 36 studies, of which 35 were preclinical and one was clinical, and it found no clinical safety data [6]. A separate 2025 literature and patent review notes that BPC-157 has not been approved by the FDA or other regulators because sufficient clinical studies are lacking [12].
In practice, much of the in vivo work comes from one research group in Zagreb (the authors of [1], [2], [4] and [5]), supported by a smaller body of mechanistic cell work from other laboratories, notably a group in Taiwan [8][9][10]. The findings below should be read with that in mind.
The clearest mechanistic study of BPC-157's vascular effects comes from Hsieh and colleagues [8]. In the chick chorioallantoic membrane assay and in endothelial tube-formation assays, BPC-157 increased vessel density. In a rat hind-limb ischemia model it accelerated recovery of blood flow measured by laser Doppler and increased vessel counts in muscle. In cultured human vascular endothelial cells it raised mRNA and protein expression of VEGF receptor 2 but not of VEGF-A itself, promoted VEGFR2 internalization, and time-dependently activated the VEGFR2-Akt-eNOS pathway. Blocking endocytosis with dynasore suppressed both the signaling and the tube formation. The distinction matters: the effect observed was on the receptor and its trafficking, not on production of the growth factor.
Reviews from the Zagreb group place this within a broader picture of 'vascular recruitment,' in which BPC-157 was reported to activate collateral vessels around occluded or injured vessels in rat models, including thrombosis after abdominal aorta anastomosis and inferior caval vein occlusion [4]. They also compare BPC-157 with the standard angiogenic growth factors EGF, FGF and VEGF, arguing that it was effective across gastrointestinal and musculoskeletal injury models without the carriers those growth factors usually need [2].
Chang and colleagues examined rat Achilles tendon fibroblasts [9]. BPC-157 accelerated the outgrowth of fibroblasts from tendon explants, but in an MTT assay it did not directly increase cell proliferation. What it did do was improve cell survival under hydrogen peroxide stress, increase migration in a transwell assay in a concentration-dependent manner, speed cell spreading, and increase F-actin formation. Western blots showed increased phosphorylation of focal adhesion kinase (FAK) and paxillin with no change in their total protein levels. The authors concluded that the pro-healing effect in tendon is more about migration and survival than about proliferation.
A follow-up study from the same group used a cDNA microarray on BPC-157-exposed tendon fibroblasts and found the growth hormone receptor among the most strongly upregulated genes [10]. The increase was confirmed at the mRNA and protein level. When growth hormone was added to the cultures, proliferation increased and the downstream kinase JAK2 was activated. This suggests one way BPC-157 could indirectly support proliferation without stimulating it directly: by making cells more responsive to a growth signal already present in vivo.
Across many rat models, the Zagreb group reports that BPC-157 interacts with the nitric oxide system, counteracting the effects of the NOS inhibitor L-NAME and modifying responses to L-arginine [1][4]. The same group has described effects on serotonergic and dopaminergic systems after peripheral delivery in rats, and implicates the Egr-1 gene, NAB2, FAK-paxillin and JAK-2 pathways [11]. These are broad, systems-level observations rather than defined receptor interactions; no specific receptor for BPC-157 has been established.
The founding musculoskeletal study used a transected rat Achilles tendon, a model with a large defect between the cut ends [5]. Compared with saline controls, BPC-157 improved biomechanical measures (load of failure and Young's modulus of elasticity), the Achilles functional index, and histology, with more fibroblasts, reticulin and collagen and fewer granulocytes. In the same paper BPC-157 had no effect on cultured tendocyte growth by itself but opposed the growth-inhibiting effect of the lipid peroxidation product 4-hydroxynonenal. The 2025 systematic review summarizes the wider preclinical set as showing improved functional, structural and biomechanical outcomes in muscle, tendon, ligament and bone injury models [6].
Given its origin, the gastrointestinal work is the largest body of evidence. In rat models the Zagreb group reports protective or healing effects on alcohol- and NSAID-induced lesions, esophagitis with lower esophageal sphincter dysfunction, intestinal anastomoses, several types of fistula, and short-bowel syndrome [1]. The same review notes that a formulation coded PL 14736 was taken into clinical trials for inflammatory bowel disease [1]; peer-reviewed efficacy results from those trials are not part of the literature summarized here.
Rat studies summarized in a 2016 review describe effects after traumatic brain injury, spinal cord compression, and peripheral nerve transection, along with attenuation of encephalopathies induced by NSAIDs, excess insulin or cuprizone [11]. These are single-group findings in rodents and have not been independently replicated at scale.
For a long time the literature had almost no pharmacokinetic data. The first formal study, published in 2022, examined rats and beagle dogs [7]. The elimination half-life of intact BPC-157 was under 30 minutes in both species, and its pharmacokinetics were linear at every level tested. Using tritium-labeled peptide, the authors showed that BPC-157 was rapidly broken down into small peptide fragments and then single amino acids, which entered normal amino acid metabolism, with urine and bile as the main excretion pathways. Stability in gastric juice [1] and rapid clearance from plasma [7] are not contradictory; they describe different environments. For in vivo design, the short plasma half-life is a reason to think carefully about sampling times and about whether an observed effect is driven by the parent peptide or by downstream signaling it set in motion.
The published work gives a practical menu of assays. For vascular questions, the chick chorioallantoic membrane assay, endothelial tube formation, and receptor internalization with an endocytosis inhibitor such as dynasore as a control [8]. For migration and survival, tendon explant outgrowth, transwell migration, spreading assays, phalloidin staining of F-actin, and oxidative-stress survival assays, paired with Western blotting for phosphorylated FAK and paxillin [9]. For gene expression, microarray or RNA-seq followed by qPCR and protein confirmation [10]. In vivo, transected Achilles tendon with biomechanical testing [5] and hind-limb ischemia with laser Doppler perfusion imaging [8] are well-described models with quantitative endpoints.
BPC-157 is supplied as a white lyophilized powder and should be stored at -20°C, sealed and dry. Let a vial come to room temperature before opening it so that moisture does not condense on the powder, dissolve it in sterile water or a suitable buffer, and divide working solutions into single-use aliquots so the stock is not repeatedly frozen and thawed. Record the lot number in your lab notebook so results can be traced back to a specific batch.
Because identity and purity determine whether an experiment means anything, confirm both. HPLC shows purity and mass spectrometry confirms that the observed mass matches the expected sequence. Northbridge Research Labs sends every batch for independent third-party testing, and published certificates are available on our COA page. For example, BPC-157 10mg lot BC10001, tested in August 2026, showed an HPLC purity of 99.32%.
Note: BPC-157 is sold strictly for laboratory research use only. It is not for human or veterinary use, and nothing in this article describes a use outside the laboratory.
Studied compound
BPC-157
The same material this research covers — 99%+ purity, independently tested, with the certificate for each batch published online.
How a single trans-3-hexenoyl group turns native GHRH into a longer-lived analogue, what the phase 3 and liver-fat trials actually found, what preclinical work showed, and how to handle tesamorelin in the lab.
What sermorelin acetate is, where the 29-residue fragment came from, how it acts at the GHRH receptor, how it compares with native GHRH, tesamorelin, CJC-1295 and ipamorelin, and how to handle it in the lab.
How retatrutide-type triple agonism at the GLP-1, GIP and glucagon receptors was designed, what the published rodent and phase 2 literature reports, and which questions remain open for laboratory study.
Research Use Only: The information in this article is for educational and research purposes only. All products mentioned are intended for laboratory research use only and are not approved for human or veterinary use.